- Shares of Northwest Biotherapeutics (NWBO +25.7%) are moving sharply higher on triple their 10-day average volume.
- Likely helping the cause is SA contributor Josh Ginsburg who says the company "poses Onyx like potential."
- Ginsburg also calls pre-clinical animal studies of DCVax-Direct "the most impressive data from any cancer study [he has] ever seen."
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs